- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
GVK Biosciences row: India, EU to meet on Jan 18 in Brussels
NEW DELHI: India and EU are expected to meet on January 18 in Brussels to iron out issues related to the ban imposed by the latter on around 700 pharma products which were clinically tested by Hyderabad-based GVK Biosciences.
Accompanied by industry representatives from Pharmaceuticals Export Promotion Council (PHARMEXCIL), senior officials from the commerce ministry will be visiting Brussels next month.
"Several issues are likely to come up during the meeting, including GVK Biosciences," an official said.
The ban imposed by the 28-nation bloc had led to deferment of talks in August between the two sides on the stalled free trade agreement, officially dubbed as Broadbased Investment and Trade Agreement (BTIA), to boost two-way commerce and investment.
India had expressed disappointment on the development and stated that the decision was taken unilaterally.
The EU had banned the marketing of around 700 generic medicines for alleged manipulation of clinical trials conducted by GVK Biosciences.
Now, India has agreed to hold consultations with the EU next month on the BTIA. In the last round of talks in May 2013, both the sides failed to bridge substantial gaps on crucial issues, including data security status for IT sector.
Accompanied by industry representatives from Pharmaceuticals Export Promotion Council (PHARMEXCIL), senior officials from the commerce ministry will be visiting Brussels next month.
"Several issues are likely to come up during the meeting, including GVK Biosciences," an official said.
The ban imposed by the 28-nation bloc had led to deferment of talks in August between the two sides on the stalled free trade agreement, officially dubbed as Broadbased Investment and Trade Agreement (BTIA), to boost two-way commerce and investment.
India had expressed disappointment on the development and stated that the decision was taken unilaterally.
The EU had banned the marketing of around 700 generic medicines for alleged manipulation of clinical trials conducted by GVK Biosciences.
Now, India has agreed to hold consultations with the EU next month on the BTIA. In the last round of talks in May 2013, both the sides failed to bridge substantial gaps on crucial issues, including data security status for IT sector.
Next Story